Publications by authors named "David F Egging"

Claim this Profile
U
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Ruud Ubink, Eef H C Dirksen, Myrthe Rouwette, Ebo S Bos, Ingrid Janssen, David F Egging

Mol Cancer Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.
Krzysztof Selmaj, Frederik Barkhof, Anna N Belova, Christian Wolf, Evelyn Rw van den Tweel, David F Egging

Mult Scler· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid screening of IgG quality attributes - effects on Fc receptor binding.
Karin P M Geuijen, Cindy Oppers-Tiemissen, David F Egging, Peter J Simons, Louis Boon

FEBS Open Bio· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Buffer and Ligand Screening for Affinity Chromatography by Multiplexed Surface Plasmon Resonance Imaging.
Karin P M Geuijen, Daniëlle E J W van Wijk-Basten, David F Egging, Richard B M Schasfoort, Michel H Eppink

Biotechnol J· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of low affinity Fcγ receptor biotinylation under controlled reaction conditions by mass spectrometry and ligand binding analysis.
Karin P M Geuijen, David F Egging, Stefanie Bartels, Jan Schouten, Richard B Schasfoort

Protein Sci· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.
Gerard Ja Rouwendal, Miranda M van der Lee, Saskia Meyer, Karli R Reiding, Jan Schouten, David F Egging

MAbs· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Ronald C Elgersma, Ruud G E Coumans, Tijl Huijbregts, Wiro M P B Menge, John A F Joosten, David F Egging

Mol Pharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
Miranda M C van der Lee, Patrick G Groothuis, Ruud Ubink, Monique A J van der Vleuten, Tanja A van Achterberg, David F Egging

Mol Cancer Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of obstetric complications and uterine connective tissue in tenascin-X-deficient humans and mice.
David F Egging, Ivonne van Vlijmen-Willems, Jiwon Choi, Anita C T M Peeters, Desiree van Rens

Cell Tissue Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis